30 days of writing #5: What is Creative Commons Licensing?

<div dir="ltr" style="text-align: left;" trbidi="on"><br /><div dir="ltr" style="text-align: left;" trbidi="on"><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiUXtijLe2fCyoOwWQAlCJlyoojFtkJtKvMQS6UDF2E0yJOTd8GTULzVaOBCDjgyn1FPOCqtVDxnljy8feNPfZqWoEPQ35n8zAVB1A7G-pxjJFb7iZrKuQhVICqFrxLniMROw3Sx-UM20eu/s1600-h/image%25255B10%25255D.png" style="margin-left: 1em; margin-right: 1em;"><img alt="image" border="0" height="89" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEikDJvlxB8uBJG202A7Q4-0scleqIkddgDLOd_WxjXTlOBOeKfGzj4dNqQTT3Z6xczNx4p9wOo2lXKdNkB-rCtzcVcWGF0ncfkzuuVEJohtF9mC-uBJ1ENdT44jgZ7MhgVihQQqZNZWdneY/?imgmax=800" style="background-image: none; border: 0px; display: inline; padding-left: 0px; padding-right: 0px; padding-top: 0px;" title="image" width="240" /></a></div><br /><span style="font-family: Arial, Helvetica, sans-serif;">How much do you know about the ins and outs of posting something you have created on the Internet? Can anyone use it and share it? Can you use and share anything someone else has posted?</span><br /><span style="font-family: Helvetica Neue, Arial, Helvetica, sans-serif; font-size: large;"><br /></span><strong><span style="font-family: Helvetica Neue, Arial, Helvetica, sans-serif; font-size: large;">Introducing Copyright on the web</span></strong><br /><span style="font-family: Arial, Helvetica, sans-serif;">The African Storybook team felt that it was important to learn about free licensing on the web right at the beginning of this course. Licensing tells others what they can and can't do with anything you put on the web. Basically, when you put something on the web it is copyright and officially no-one should use it. But if you want people to use your work in any way it you need to say something to give permission.  This applies to the stories we'll be donating to the African Storybook Project. We need to put a specific free license on them (very simple to do) to give other teachers and Grades 1-3 children in Africa permission to create a new story from them, translate them, make them easier or more difficult etc. But the original story will still be there on the web in its entirety. You will be the only one who can actually sell your story if you should want to. </span><br /><span style="font-family: Helvetica Neue, Arial, Helvetica, sans-serif; font-size: large;"><br /></span><strong><span style="font-family: Helvetica Neue, Arial, Helvetica, sans-serif; font-size: large;">Creative Commons Licensing</span></strong><br /><span style="font-family: Arial, Helvetica, sans-serif;">The licensing we are talking about is called Creative Commons licensing.  This video gives a great introduction to licensing on the web and shows six Creative Commons licenses one could choose from.</span><br /><span style="font-family: Arial, Helvetica, sans-serif; font-size: x-small;"><br /></span><iframe allowfullscreen="" frameborder="0" height="315" src="http://www.youtube.com/embed/mAk9H1N8beU" width="420"></iframe><br /><a href="http://www.youtube.com/watch?v=mAk9H1N8beU">http://www.youtube.com/watch?v=mAk9H1N8beU</a><br /><span style="font-size: x-small;"><br /></span><span style="font-family: Arial, Helvetica, sans-serif;">These are the six licenses. . </span><br /><span style="font-size: x-small;"><br /></span><br /><div class="separator" style="clear: both; text-align: center;"><span style="font-size: x-small; margin-left: 1em; margin-right: 1em;"><img alt="image" border="0" height="300" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjRRcP4N2mpwyK041kGgzR9swaOMNA6DciZzIIg6qaSoZQ-eSkFRrWma0Zn7iUD_sMMhhpNhdgk8Nvrw24iq0Pn6Obvb8csFURc8vY56jJdkcVIsMTd8qgvw40145LxSrw4N0lNsw9OZoG2/?imgmax=800" style="background-image: none; border-width: 0px; display: inline; margin: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px;" title="image" width="400" /></span></div><br /><span style="font-size: x-small;"><br /></span><span style="font-family: Arial, Helvetica, sans-serif;">This is how they look in their official form – the license choice can just be copied and pasted on to something one creates and it’s done. It is as simple as that. </span><br /><span style="font-size: x-small;"><br /></span><br /><div class="separator" style="clear: both; text-align: center;"><span style="font-size: x-small; margin-left: 1em; margin-right: 1em;"><img alt="image" border="0" height="301" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjhTw9ArsIprPKziyAYxQ4lenN2-t9sn5L-DZUKlWvqPtXSkXqDRapHjySAtH3i-c2jWlSUwFc2Ru77VFFGJWai0iobCmsm8YK6gSk4Z3n4TETr8JyRDOpARSQ83qo4TKWBdGA7TrQd3Wx9/?imgmax=800" style="background-image: none; border-width: 0px; display: inline; margin: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px;" title="image" width="400" /></span></div><br /><strong><span style="font-size: x-small;"><br /></span></strong><strong><span style="font-size: x-small;"><br /></span></strong><strong><span style="font-family: Helvetica Neue, Arial, Helvetica, sans-serif; font-size: large;">An example - Using images on the web</span></strong><br /><span style="font-family: Arial, Helvetica, sans-serif;">Let’s take the example of using images on the web. Can we simply just find a picture in Google and use it as if it was our own on the web? </span><br /><span style="font-family: Arial, Helvetica, sans-serif;"><br /></span><span style="font-family: Arial, Helvetica, sans-serif;">Generally, permission to use images ranges from pictures that are in the public domain (anyone can use them) to images that are copyright and require permission to use. Creative Commons licenses grant permission in advance. All Creative Commons licenses require 'attribution' (meaning you have to credit the person who created the item). Most images copyright online are covered by Creative Commons licensing. This means that some sites allow you to use their images but you need to give attribution to them. </span><br /><span style="font-family: Arial, Helvetica, sans-serif;"><br /></span> <br /><b><span style="font-family: Helvetica Neue, Arial, Helvetica, sans-serif; font-size: large;">How do you find out which creative works are covered by this licensing?</span></b><br /><br /><ul style="text-align: left;"><li><span style="font-family: Arial, Helvetica, sans-serif;">This website shows you how to use Creative Commons to find free images, audio and video for your website etc</span><b style="font-family: Arial, Helvetica, sans-serif;">: </b><a href="http://search.creativecommons.org/" style="font-family: Arial, Helvetica, sans-serif;">http://search.creativecommons.org/</a></li><li><span style="font-family: Arial, Helvetica, sans-serif;">Take a look at the video below – it explains really well how to go about searching for something with a Creative Commons license. This video explains the website mentioned above - </span><a href="http://search.creativecommons.org/" style="font-family: Arial, Helvetica, sans-serif;">http://search.creativecommons.org/</a><span style="font-family: Arial, Helvetica, sans-serif;">. </span></li></ul><br /><div><iframe allowfullscreen="" frameborder="0" height="315" src="http://www.youtube.com/embed/YvsbJaJeFGY" width="420"></iframe></div><div><a href="http://www.youtube.com/watch?v=YvsbJaJeFGY" style="font-family: Arial, Helvetica, sans-serif;">http://www.youtube.com/watch?v=YvsbJaJeFGY</a></div><a href="http://www.youtube.com/watch?v=XlNM1Ak95oU"><span style="background-color: yellow; font-family: Arial, Helvetica, sans-serif;"></span></a><br /><span style="font-family: Helvetica Neue, Arial, Helvetica, sans-serif; font-size: large;"><b>How do you add a license to your own work?</b></span><br /><span style="font-family: Arial, Helvetica, sans-serif;"> </span><span style="font-family: Arial, Helvetica, sans-serif;">If you open <a href="http://creativecommons.org/">http://creativecommons.org/ </a>you will see a link to start the process of putting one of the licenses on to your work. As the website says, "<i>There is no registration to use the Creative Commons licenses. Licensing a work is as simple as selecting which of the six licenses best meets your goals, and then marking your work in some way so that others know that you have chosen to release the work under the terms of that license. Our license-choosing tool can help you select the right license</i>." </span><br /><br /><b><span style="font-family: Helvetica Neue, Arial, Helvetica, sans-serif; font-size: large;">What is the public domain?</span></b><br /><span style="font-family: Arial, Helvetica, sans-serif;">Sometimes people wish for a piece of their own work to be freely available to everyone to use with no strings attached, and put the work in the public domain. This isn't very hard to do — the copyright holder merely has to make a statement that they release all rights to the work. Once this irrevocable act is complete they no longer have any power over how the work is used since it is then owned by the public as a whole. <a href="http://en.wikipedia.org/wiki/Wikipedia:Granting_work_into_the_public_domain">http://en.wikipedia.org/wiki/Wikipedia:Granting_work_into_the_public_domain</a> </span><br /><span style="font-family: Arial, Helvetica, sans-serif;"><u></u> </span><br /><span style="font-family: Arial, Helvetica, sans-serif;">When it comes to the public domain, there is no catch. If a book, song, movie, or artwork is in the public domain, then it is not protected by intellectual property laws (copyright, trademark, or patent laws)—which means it’s free for you to use without permission. This would include works and inventions whose copyright has expired due to age or lack of renewal. </span><br /><span style="font-family: Arial, Helvetica, sans-serif;"><br /></span> <span style="font-family: Helvetica Neue, Arial, Helvetica, sans-serif; font-size: large;"><strong>Saide’s guide to using copyright</strong></span><br /><span style="font-family: Arial, Helvetica, sans-serif;">Saide (South African Institute of Distance Education) who is adminstering this project has a very good guide to licensing which they call ‘The OER Africa Copyright and licensing toolkit’. It can be found here":</span><br /><a href="http://www.oerafrica.org/copyright/CopyrightandLicencingToolkit/tabid/1781/Default.aspx"><span style="font-family: Arial, Helvetica, sans-serif;">http://www.oerafrica.org/copyright/CopyrightandLicencingToolkit/tabid/1781/Default.aspx</span></a><br /><span style="font-family: Arial, Helvetica, sans-serif;">  </span><br /><span style="font-family: Helvetica Neue, Arial, Helvetica, sans-serif; font-size: large;"><strong>Explore royalty free resources</strong></span><br /><span style="font-family: Arial, Helvetica, sans-serif;">Fortunately for us there are loads of resources that are freely available to us. Here are just a few. </span><br /><br /><ul style="text-align: left;"><li><a href="http://larryferlazzo.edublogs.org/2008/12/08/the-best-places-to-get-royalty-free-music-sound-effects/" style="font-family: Arial, Helvetica, sans-serif;">Larry Ferlazzo</a><span style="font-family: Arial, Helvetica, sans-serif;"> - The Best Places To Get Royalty-Free Music & Sound Effects from Larry Ferlazzo</span><a href="http://www.photl.com/en/" style="font-family: Arial, Helvetica, sans-serif;">Photl.com</a><span style="font-family: Arial, Helvetica, sans-serif;"> has 160,000 copyright-free images available.</span><a href="http://larryferlazzo.edublogs.org/2008/10/11/the-best-online-sources-for-images/" style="font-family: Arial, Helvetica, sans-serif;">Larry Ferlazzo</a><span style="font-family: Arial, Helvetica, sans-serif;"> Best online sources for images</span><a href="http://www.phillipmartin.info/clipart/homepage.htm" style="font-family: Arial, Helvetica, sans-serif;">Free clipart</a><span style="font-family: Arial, Helvetica, sans-serif;"> Phil Martin’s collection</span></li><li><a href="http://commons.wikimedia.org/wiki/Main_Page" style="font-family: Arial, Helvetica, sans-serif;">Wikimedia Commons</a><span style="font-family: Arial, Helvetica, sans-serif;"> (4 million images in the public domain)</span></li><li><a href="http://www.freeimages.co.uk/" style="font-family: Arial, Helvetica, sans-serif;">Free Images</a><span style="font-family: Arial, Helvetica, sans-serif;"> (6000 stock photos, and they require you to credit them as the source)</span></li><li><a href="http://worldimages.sjsu.edu/" style="font-family: Arial, Helvetica, sans-serif;">World Images</a><span style="font-family: Arial, Helvetica, sans-serif;"> (80,000 photos from the California State University IMAGE project, under a non-commercial  CC license)</span></li><li><a href="http://www.flickr.com/photos/eltpics/" style="font-family: Arial, Helvetica, sans-serif;">ELT Pics</a><span style="font-family: Arial, Helvetica, sans-serif;"> (Images taken by teachers for teachers, collected via Twitter and stored on Flickr, under a non-commercial CC license)</span></li><li><a href="http://photopin.com/" style="font-family: Arial, Helvetica, sans-serif;">PhotoPin</a><span style="font-family: Arial, Helvetica, sans-serif;"> (a search engine that finds Creative Commons images)</span></li><li><a href="http://www.wylio.com/" style="font-family: Arial, Helvetica, sans-serif;">Wylio</a><span style="font-family: Arial, Helvetica, sans-serif;">- Search engine for CC images for bloggers</span></li><li><a href="http://www.photoxpress.com/" style="font-family: Arial, Helvetica, sans-serif;">PhotoeXpress</a><span style="font-family: Arial, Helvetica, sans-serif;">- lengthy registration process but you get 10 free quality stock images a day with a search engine and you don't have to attribute.</span></li><li><a href="http://ccmixter.org/" style="font-family: Arial, Helvetica, sans-serif;">CCMixter.org</a><span style="font-family: Arial, Helvetica, sans-serif;">- Great songs, music that is Creative Commons! Just give attribution</span></li><li><a href="http://www.freesound.org/" style="font-family: Arial, Helvetica, sans-serif;">FreeSound</a><span style="font-family: Arial, Helvetica, sans-serif;">- Free sound files and clips for use!</span></li><li><a href="http://www.soundzabound.com/" style="font-family: Arial, Helvetica, sans-serif;">Soundzabound</a><span style="font-family: Arial, Helvetica, sans-serif;">- royalty free music library</span></li></ul></div></div>

30 Days of Writing 30 days of writing #5: What is Creative Commons Licensing?

How much do you know about the ins and outs of posting something you have created on the Internet? Can anyone use it and share it? Can you u...

Read more »

A51 New Smart Phone launched by Videocon

<div dir="ltr" style="text-align: left;" trbidi="on"><div class="separator" style="clear: both; text-align: center;"><a href="https://www.blogger.com/blogger.g?blogID=7510546871509957516" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"></a></div><div class="separator" style="clear: both; text-align: center;"><u><img border="0" height="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh0SLA98DHUlOWjAb1vY8L8G52RczlxC4nt3Qb0El6l0j-Yds8DjXmyFrKBoWPwSlQ_OSHeJNQJYbsRUM9FkSTS-OXxznCPxF1WnfiAqAdfAWrVdMEL5n2m-9aYWL0a-i3GaaGc0okqpK4/s320/A51.jpg" width="174" /></u></div><!--[if gte mso 9]><xml> <o:OfficeDocumentSettings> <o:AllowPNG/> </o:OfficeDocumentSettings></xml><![endif]--><br /><!--[if gte mso 9]><xml> <w:WordDocument> <w:View>Normal</w:View> <w:Zoom>0</w:Zoom> <w:TrackMoves/> <w:TrackFormatting/> <w:PunctuationKerning/> <w:ValidateAgainstSchemas/> <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid> <w:IgnoreMixedContent>false</w:IgnoreMixedContent> <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText> <w:DoNotPromoteQF/> <w:LidThemeOther>EN-US</w:LidThemeOther> <w:LidThemeAsian>X-NONE</w:LidThemeAsian> <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript> <w:Compatibility> <w:BreakWrappedTables/> <w:SnapToGridInCell/> <w:WrapTextWithPunct/> <w:UseAsianBreakRules/> <w:DontGrowAutofit/> <w:SplitPgBreakAndParaMark/> <w:EnableOpenTypeKerning/> <w:DontFlipMirrorIndents/> <w:OverrideTableStyleHps/> </w:Compatibility> <m:mathPr> <m:mathFont m:val="Cambria Math"/> <m:brkBin m:val="before"/> <m:brkBinSub m:val="--"/> <m:smallFrac m:val="off"/> <m:dispDef/> <m:lMargin m:val="0"/> <m:rMargin m:val="0"/> <m:defJc m:val="centerGroup"/> <m:wrapIndent m:val="1440"/> <m:intLim m:val="subSup"/> <m:naryLim m:val="undOvr"/> </m:mathPr></w:WordDocument></xml><![endif]--><!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true" DefSemiHidden="true" DefQFormat="false" DefPriority="99" LatentStyleCount="267"> <w:LsdException Locked="false" Priority="0" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Normal"/> <w:LsdException Locked="false" Priority="9" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="heading 1"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/> <w:LsdException Locked="false" Priority="39" Name="toc 1"/> <w:LsdException Locked="false" Priority="39" Name="toc 2"/> <w:LsdException Locked="false" Priority="39" Name="toc 3"/> <w:LsdException Locked="false" Priority="39" Name="toc 4"/> <w:LsdException Locked="false" Priority="39" Name="toc 5"/> <w:LsdException Locked="false" Priority="39" Name="toc 6"/> <w:LsdException Locked="false" Priority="39" Name="toc 7"/> <w:LsdException Locked="false" Priority="39" Name="toc 8"/> <w:LsdException Locked="false" Priority="39" Name="toc 9"/> <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/> <w:LsdException Locked="false" Priority="10" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Title"/> <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/> <w:LsdException Locked="false" Priority="11" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/> <w:LsdException Locked="false" Priority="22" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Strong"/> <w:LsdException Locked="false" Priority="20" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/> <w:LsdException Locked="false" Priority="59" SemiHidden="false" UnhideWhenUsed="false" Name="Table Grid"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/> <w:LsdException Locked="false" Priority="1" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 1"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 1"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 1"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/> <w:LsdException Locked="false" Priority="34" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/> <w:LsdException Locked="false" Priority="29" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Quote"/> <w:LsdException Locked="false" Priority="30" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 1"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 1"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 2"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 2"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 2"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 2"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 2"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 3"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 3"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 3"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 3"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 3"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 4"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 4"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 4"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 4"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 4"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 5"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 5"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 5"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 5"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 5"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 6"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 6"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 6"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 6"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 6"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/> <w:LsdException Locked="false" Priority="19" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/> <w:LsdException Locked="false" Priority="21" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/> <w:LsdException Locked="false" Priority="31" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/> <w:LsdException Locked="false" Priority="32" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/> <w:LsdException Locked="false" Priority="33" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Book Title"/> <w:LsdException Locked="false" Priority="37" Name="Bibliography"/> <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/> </w:LatentStyles></xml><![endif]--><!--[if gte mso 10]><style> /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin-top:0in; mso-para-margin-right:0in; mso-para-margin-bottom:10.0pt; mso-para-margin-left:0in; line-height:115%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin;} </style><![endif]--> <br /><div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in;"><b style="mso-bidi-font-weight: normal;"><br /> </b></div><div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in;"><b style="mso-bidi-font-weight: normal;"><span id="goog_475299184"></span><span id="goog_475299185"></span>A51 Anderoid </b></div><div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in;"><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-fareast-font-family: "Times New Roman";">The Videocon Launched New Anderoid Smart Phone. Which have 5" Big Screen, Phablet based on Android 4.0 (Ice cream Sandwich) OS powered by 1 Ghz Dual Core processor & 3.75 G</span></div><div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in;"><u><b><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-fareast-font-family: "Times New Roman";">Key Features</span></b></u></div><br /><ul><li><span style="font-family: Symbol; font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt "Times New Roman";">         </span></span></span><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-fareast-font-family: "Times New Roman";">Large 12.6 cm or 5" FWVGA Capacitive Multi touch screen</span></li><li><span style="font-family: Symbol; font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt "Times New Roman";">         </span></span></span><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-fareast-font-family: "Times New Roman";">Powered by Android 4.0 (Ice Cream Sandwich) OS</span></li><li><span style="font-family: Symbol; font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt "Times New Roman";">         </span></span></span><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-fareast-font-family: "Times New Roman";">Dual SIM, Dual Standby</span></li><li><span style="font-family: Symbol; font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt "Times New Roman";">         </span></span></span><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-fareast-font-family: "Times New Roman";">1 Ghz Dual Core Processor</span></li><li><span style="font-family: Symbol; font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt "Times New Roman";">         </span></span></span><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-fareast-font-family: "Times New Roman";">2000 mAh Battery</span></li><li><span style="font-family: Symbol; font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt "Times New Roman";">         </span></span></span><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-fareast-font-family: "Times New Roman";">3.75 G, Wi-Fi, 802.11b/gn, GPS/A-GPS & A2DP Bluetooth</span></li><li><span style="font-family: Symbol; font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt "Times New Roman";">         </span></span></span><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-fareast-font-family: "Times New Roman";">Rear – 5 MP Camera Auto Focus with Flash, Front VGA Camera</span></li><li><span style="font-family: Symbol; font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt "Times New Roman";">         </span></span></span><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-fareast-font-family: "Times New Roman";">Expandable Memory upto 32 GB</span></li><li><span style="font-family: Symbol; font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt "Times New Roman";">         </span></span></span><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-fareast-font-family: "Times New Roman";">G Sensor and Proximity Sensor</span></li><li><span style="font-family: Symbol; font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt "Times New Roman";">         </span></span></span><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-fareast-font-family: "Times New Roman";">TOI, Whatsapp, Facebook, Saavn, Fun Zone</span></li></ul><br /><div class="MsoListParagraphCxSpLast" style="margin-bottom: .0001pt; margin-bottom: 0in; mso-add-space: auto;"><br /></div><div align="center" class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: center;"><b style="mso-bidi-font-weight: normal;"><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-fareast-font-family: "Times New Roman";">A51 Specification</span></b></div><div align="center" class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: center;"><b style="mso-bidi-font-weight: normal;"><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-fareast-font-family: "Times New Roman";"><!--[if gte mso 9]><xml> <o:OfficeDocumentSettings> <o:AllowPNG/> </o:OfficeDocumentSettings></xml><![endif]--></span></b></div><br /><div align="center" class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; text-align: center;"><b style="mso-bidi-font-weight: normal;"><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; line-height: 115%; mso-fareast-font-family: "Times New Roman";"><!--[if gte mso 9]><xml> <w:WordDocument> <w:View>Normal</w:View> <w:Zoom>0</w:Zoom> <w:TrackMoves/> <w:TrackFormatting/> <w:PunctuationKerning/> <w:ValidateAgainstSchemas/> <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid> <w:IgnoreMixedContent>false</w:IgnoreMixedContent> <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText> <w:DoNotPromoteQF/> <w:LidThemeOther>EN-US</w:LidThemeOther> <w:LidThemeAsian>X-NONE</w:LidThemeAsian> <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript> <w:Compatibility> <w:BreakWrappedTables/> <w:SnapToGridInCell/> <w:WrapTextWithPunct/> <w:UseAsianBreakRules/> <w:DontGrowAutofit/> <w:SplitPgBreakAndParaMark/> <w:EnableOpenTypeKerning/> <w:DontFlipMirrorIndents/> <w:OverrideTableStyleHps/> </w:Compatibility> <m:mathPr> <m:mathFont m:val="Cambria Math"/> <m:brkBin m:val="before"/> <m:brkBinSub m:val="--"/> <m:smallFrac m:val="off"/> <m:dispDef/> <m:lMargin m:val="0"/> <m:rMargin m:val="0"/> <m:defJc m:val="centerGroup"/> <m:wrapIndent m:val="1440"/> <m:intLim m:val="subSup"/> <m:naryLim m:val="undOvr"/> </m:mathPr></w:WordDocument></xml><![endif]--><!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true" DefSemiHidden="true" DefQFormat="false" DefPriority="99" LatentStyleCount="267"> <w:LsdException Locked="false" Priority="0" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Normal"/> <w:LsdException Locked="false" Priority="9" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="heading 1"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/> <w:LsdException Locked="false" Priority="39" Name="toc 1"/> <w:LsdException Locked="false" Priority="39" Name="toc 2"/> <w:LsdException Locked="false" Priority="39" Name="toc 3"/> <w:LsdException Locked="false" Priority="39" Name="toc 4"/> <w:LsdException Locked="false" Priority="39" Name="toc 5"/> <w:LsdException Locked="false" Priority="39" Name="toc 6"/> <w:LsdException Locked="false" Priority="39" Name="toc 7"/> <w:LsdException Locked="false" Priority="39" Name="toc 8"/> <w:LsdException Locked="false" Priority="39" Name="toc 9"/> <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/> <w:LsdException Locked="false" Priority="10" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Title"/> <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/> <w:LsdException Locked="false" Priority="11" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/> <w:LsdException Locked="false" Priority="22" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Strong"/> <w:LsdException Locked="false" Priority="20" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/> <w:LsdException Locked="false" Priority="59" SemiHidden="false" UnhideWhenUsed="false" Name="Table Grid"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/> <w:LsdException Locked="false" Priority="1" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 1"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 1"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 1"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/> <w:LsdException Locked="false" Priority="34" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/> <w:LsdException Locked="false" Priority="29" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Quote"/> <w:LsdException Locked="false" Priority="30" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 1"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 1"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 2"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 2"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 2"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 2"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 2"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 3"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 3"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 3"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 3"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 3"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 4"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 4"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 4"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 4"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 4"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 5"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 5"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 5"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 5"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 5"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 6"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 6"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 6"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 6"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 6"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/> <w:LsdException Locked="false" Priority="19" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/> <w:LsdException Locked="false" Priority="21" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/> <w:LsdException Locked="false" Priority="31" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/> <w:LsdException Locked="false" Priority="32" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/> <w:LsdException Locked="false" Priority="33" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Book Title"/> <w:LsdException Locked="false" Priority="37" Name="Bibliography"/> <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/> </w:LatentStyles></xml><![endif]--><!--[if gte mso 10]><style> /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin-top:0in; mso-para-margin-right:0in; mso-para-margin-bottom:10.0pt; mso-para-margin-left:0in; line-height:115%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin;} table.MsoTableLightShading {mso-style-name:"Light Shading"; mso-tstyle-rowband-size:1; mso-tstyle-colband-size:1; mso-style-priority:60; mso-style-unhide:no; border-top:solid black 1.0pt; mso-border-top-themecolor:text1; border-left:none; border-bottom:solid black 1.0pt; mso-border-bottom-themecolor:text1; border-right:none; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; color:black; mso-themecolor:text1; mso-themeshade:191;} table.MsoTableLightShadingFirstRow {mso-style-name:"Light Shading"; mso-table-condition:first-row; mso-style-priority:60; mso-style-unhide:no; mso-tstyle-border-top:1.0pt solid black; mso-tstyle-border-top-themecolor:text1; mso-tstyle-border-left:cell-none; mso-tstyle-border-bottom:1.0pt solid black; mso-tstyle-border-bottom-themecolor:text1; mso-tstyle-border-right:cell-none; mso-tstyle-border-insideh:cell-none; mso-tstyle-border-insidev:cell-none; mso-para-margin-top:0in; mso-para-margin-bottom:0in; mso-para-margin-bottom:.0001pt; line-height:normal; mso-ansi-font-weight:bold; mso-bidi-font-weight:bold;} table.MsoTableLightShadingLastRow {mso-style-name:"Light Shading"; mso-table-condition:last-row; mso-style-priority:60; mso-style-unhide:no; mso-tstyle-border-top:1.0pt solid black; mso-tstyle-border-top-themecolor:text1; mso-tstyle-border-left:cell-none; mso-tstyle-border-bottom:1.0pt solid black; mso-tstyle-border-bottom-themecolor:text1; mso-tstyle-border-right:cell-none; mso-tstyle-border-insideh:cell-none; mso-tstyle-border-insidev:cell-none; mso-para-margin-top:0in; mso-para-margin-bottom:0in; mso-para-margin-bottom:.0001pt; line-height:normal; mso-ansi-font-weight:bold; mso-bidi-font-weight:bold;} table.MsoTableLightShadingFirstCol {mso-style-name:"Light Shading"; mso-table-condition:first-column; mso-style-priority:60; mso-style-unhide:no; mso-ansi-font-weight:bold; mso-bidi-font-weight:bold;} table.MsoTableLightShadingLastCol {mso-style-name:"Light Shading"; mso-table-condition:last-column; mso-style-priority:60; mso-style-unhide:no; mso-ansi-font-weight:bold; mso-bidi-font-weight:bold;} table.MsoTableLightShadingOddColumn {mso-style-name:"Light Shading"; mso-table-condition:odd-column; mso-style-priority:60; mso-style-unhide:no; mso-tstyle-shading:silver; mso-tstyle-shading-themecolor:text1; mso-tstyle-shading-themetint:63; mso-tstyle-border-left:cell-none; mso-tstyle-border-right:cell-none; mso-tstyle-border-insideh:cell-none; mso-tstyle-border-insidev:cell-none;} table.MsoTableLightShadingOddRow {mso-style-name:"Light Shading"; mso-table-condition:odd-row; mso-style-priority:60; mso-style-unhide:no; mso-tstyle-shading:silver; mso-tstyle-shading-themecolor:text1; mso-tstyle-shading-themetint:63; mso-tstyle-border-left:cell-none; mso-tstyle-border-right:cell-none; mso-tstyle-border-insideh:cell-none; mso-tstyle-border-insidev:cell-none;} </style><![endif]--> <table border="1" cellpadding="0" cellspacing="0" class="MsoTableLightShading" style="border-collapse: collapse; border: none; mso-border-bottom-alt: solid black 1.0pt; mso-border-bottom-themecolor: text1; mso-border-top-alt: solid black 1.0pt; mso-border-top-themecolor: text1; mso-padding-alt: 0in 5.4pt 0in 5.4pt; mso-yfti-tbllook: 1696;"> <tbody><tr style="mso-yfti-firstrow: yes; mso-yfti-irow: -1;"> <td style="border-bottom: solid black 1.0pt; border-left: none; border-right: none; border-top: solid black 1.0pt; mso-border-bottom-themecolor: text1; mso-border-top-themecolor: text1; padding: 0in 5.4pt 0in 5.4pt; width: 185.4pt;" valign="top" width="247"><div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; mso-yfti-cnfc: 5;"><b><span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-themecolor: text1; mso-themeshade: 191;">Key Points</span></b></div></td> <td style="border-bottom: solid black 1.0pt; border-left: none; border-right: none; border-top: solid black 1.0pt; mso-border-bottom-themecolor: text1; mso-border-top-themecolor: text1; padding: 0in 5.4pt 0in 5.4pt; width: 333.0pt;" valign="top" width="444"><div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; mso-yfti-cnfc: 1;"><b><span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-themecolor: text1; mso-themeshade: 191;">Features</span></b></div></td> </tr><tr style="mso-yfti-irow: 0;"> <td style="border: none; padding: 0in 5.4pt 0in 5.4pt; width: 185.4pt;" valign="top" width="247"><div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; mso-yfti-cnfc: 4;"><b><span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-themecolor: text1; mso-themeshade: 191;">Dimension</span></b></div></td> <td style="border: none; padding: 0in 5.4pt 0in 5.4pt; width: 333.0pt;" valign="top" width="444"><div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in;"><span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-themecolor: text1; mso-themeshade: 191;">146.2 x 78.4 x11.3 mm</span></div></td> </tr><tr style="mso-yfti-irow: 1;"> <td style="border: none; padding: 0in 5.4pt 0in 5.4pt; width: 185.4pt;" valign="top" width="247"><div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; mso-yfti-cnfc: 4;"><b><span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-themecolor: text1; mso-themeshade: 191;">Camera</span></b></div></td> <td style="border: none; padding: 0in 5.4pt 0in 5.4pt; width: 333.0pt;" valign="top" width="444"><div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in;"><span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-themecolor: text1; mso-themeshade: 191;">Rear – 5MP Auto Focus with Flash</span></div><div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in;"><span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-themecolor: text1; mso-themeshade: 191;">Front VGA</span></div></td> </tr><tr style="mso-yfti-irow: 2;"> <td style="border: none; padding: 0in 5.4pt 0in 5.4pt; width: 185.4pt;" valign="top" width="247"><div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; mso-yfti-cnfc: 4;"><b><span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-themecolor: text1; mso-themeshade: 191;">Entertainment</span></b></div></td> <td style="border: none; padding: 0in 5.4pt 0in 5.4pt; width: 333.0pt;" valign="top" width="444"><div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in;"><span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-themecolor: text1; mso-themeshade: 191;">Audio/Video Formats (MP3, AAC, MPEG4, H.263, H.264, 3GP)</span></div><div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in;"><span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-themecolor: text1; mso-themeshade: 191;">Flat Wire Head Set</span></div><div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in;"><span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-themecolor: text1; mso-themeshade: 191;">FM Radio</span></div></td> </tr><tr style="mso-yfti-irow: 3;"> <td style="border: none; padding: 0in 5.4pt 0in 5.4pt; width: 185.4pt;" valign="top" width="247"><div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; mso-yfti-cnfc: 4;"><b><span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-themecolor: text1; mso-themeshade: 191;">Memory</span></b></div></td> <td style="border: none; padding: 0in 5.4pt 0in 5.4pt; width: 333.0pt;" valign="top" width="444"><div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in;"><span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-themecolor: text1; mso-themeshade: 191;">Up to 32 GB Expandable Memory</span></div><div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in;"><span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-themecolor: text1; mso-themeshade: 191;">4 GB ROM + 512 MB RAM</span></div><div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in;"><span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-themecolor: text1; mso-themeshade: 191;">Unlimited Phonebook and SMS Memory</span></div></td> </tr><tr style="mso-yfti-irow: 4;"> <td style="border: none; padding: 0in 5.4pt 0in 5.4pt; width: 185.4pt;" valign="top" width="247"><div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; mso-yfti-cnfc: 4;"><b><span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-themecolor: text1; mso-themeshade: 191;">Connectivity</span></b></div></td> <td style="border: none; padding: 0in 5.4pt 0in 5.4pt; width: 333.0pt;" valign="top" width="444"><div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in;"><span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-themecolor: text1; mso-themeshade: 191;">GSM/GPRS/EDGE: 900/1800 MHz, UMTS/WCDMA/HSPA: 2100 MHz</span></div><div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in;"><span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-themecolor: text1; mso-themeshade: 191;">Bluetooth V 3.0 with A2DP support</span></div><div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in;"><span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-themecolor: text1; mso-themeshade: 191;">Micro USB Support</span></div></td> </tr><tr style="mso-yfti-irow: 5; mso-yfti-lastrow: yes;"> <td style="border-bottom: solid black 1.0pt; border: none; mso-border-bottom-themecolor: text1; padding: 0in 5.4pt 0in 5.4pt; width: 185.4pt;" valign="top" width="247"><div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; mso-yfti-cnfc: 4;"><b><span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-themecolor: text1; mso-themeshade: 191;">Color</span></b></div></td> <td style="border-bottom: solid black 1.0pt; border: none; mso-border-bottom-themecolor: text1; padding: 0in 5.4pt 0in 5.4pt; width: 333.0pt;" valign="top" width="444"><div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in;"><span style="color: black; font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-themecolor: text1; mso-themeshade: 191;">Bluish Black</span></div></td> </tr></tbody></table>  </span></b></div></div>Published by <a href="https://plus.google.com/105898721501858863999" rel="author">Pawan Saini</a>

mobile news A51 New Smart Phone launched by Videocon

A51 Anderoid The Videocon Launched New Anderoid Smart Phone. Which have 5" Big Screen, Phablet based on Android 4.0 (Ice cream Sandwi...

Read more »

An Easy Guide to Gaining Followers and Being Followed on Twitter

<table cellpadding="0" cellspacing="0" class="tr-caption-container zemanta-img" style="float: right; margin-right: 1em; text-align: right;"><tbody><tr><td style="text-align: center;"><div class="zemanta-img"><a href="http://www.mysecuritysign.com/take-no-bullies" imageanchor="1" style="margin-bottom: 1em; margin-left: auto; margin-right: auto; text-align: clear:right;"><img alt="Twitter" border="0" class="zemanta-img-inserted" height="200" src="http://www.mysecuritysign.com/img/lg/L/Tweet-Be-Tweeted-Same-Label-LB-1988.gif" style="border: none; font-size: 0.8em;" width="200" /></a></div></td></tr><tr><td class="tr-caption zemanta-img-attribution" style="text-align: center; width: 400px;"><a href="http://www.mysecuritysign.com/take-no-bullies" target="_blank">Twitter</a> (Photo credits: <a href="http://www.mysecuritysign.com/" target="_blank">www.mysecuritysign.com</a>)</td></tr></tbody></table><a class="zem_slink" href="http://twitter.com/" rel="homepage" target="_blank" title="Twitter">Twitter</a> is an interesting mix of people. As you join Twitter, you need to decide how you will follow and unfollow others. I thought it would be helpful if some of us can mutually share how we determine who we follow and unfollow people. If those who have been doing this a while can mutually cooperate to stimulate conversations about how we use Twitter, it can  help others.<br /><div><br /></div><div>The scary thing about writing such a list is when you've been tweeting as long as I have, I've made many of the mistakes I mention myself. ;-) So, I submit this list as just guidelines knowing I'm not so perfect either.<br /><div><br /></div><h2>I follow people who:</h2><div><ul><li><b>Talk with me about interesting things.</b><br />I most often follow people on the spot who have interesting conversations with me that make me a better person. Replying to people or modifying the tweet (MT) instead of just retweeting are two quick ways to gain followers from most people.<br /></li><li><b>Demonstrate by their words that they are the exceptional kind of person I'd like to be around.</b><br />You become like those you are around. (<a href="http://coolcatteacher.blogspot.com/2006/12/how-to-create-your-circle-of-wise-how.html">How to build your circle of the wise</a>.) Let' me give you an example. Look at the conversation below.<br /><br /><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgGIfiren1GUoeDxdFyn9oRQ-O20vS5RboX3uddbbfJtawi7gOGjPNfJN0loSQMtZu_V9tuPhCHh4eoIkWelPDZeI5aoB45fC0b7_fGN0f8V0aq-HP3WogC3GAGWn2XIMuvH5xxAWjR_HEi/s1600/1-kimberly-twitter-follow.JPG" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" height="374" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgGIfiren1GUoeDxdFyn9oRQ-O20vS5RboX3uddbbfJtawi7gOGjPNfJN0loSQMtZu_V9tuPhCHh4eoIkWelPDZeI5aoB45fC0b7_fGN0f8V0aq-HP3WogC3GAGWn2XIMuvH5xxAWjR_HEi/s400/1-kimberly-twitter-follow.JPG" width="400" /></a><br />Kimberly <a href="https://twitter.com/khurdhorst">@khurdhorst</a> is my kind of teacher. She showed by her tweet that she loves a child. She has no benefit from tweeting that except just letting out a little piece of who she is. We need educators on Twitter like Kimberly who show their unashamed love of their students and the greatest profession. She's my my of educator. I followed her immediately just for that one tweet.<br /></li><li><b>Demonstrate a common interest in things I care about.</b><br />It may be silly but sometimes I do a litmus test to find people who are just funny and cool. They are games, but I've found the best educators and people to follow. I may tweet a line from one of my favorite movies and follow the people that reply. It may be those who reply to a tweet I wrote that meant a lot to me. It may be those who cared enough to tweet encouragement if I was having a rough day.<br /></li><li><b>People who are born encouragers.</b><br />I first followed <a class="g-profile" href="http://plus.google.com/104605097393315895329" target="_blank">+Jerry Blumengarten</a> @<a href="https://twitter.com/cybraryman1">cybraryman1 </a> because he tweeted me encouragement as I ran. He was so kind. Then, when I followed him, he'd dm me to ask me if I was ok or encourage me when I needed a push. There are people who notice others and care about the person.<br /></li><li><b>People who are bridge builders</b><br />There are those who tweet great things but also take time to reply and encourage a lot of people. Often these people are like  <a class="g-profile" href="http://plus.google.com/107191215621360482175" target="_blank">+Tom Whitby</a> <a href="https://twitter.com/tomwhitby">@tomwhitby</a>and <a class="g-profile" href="http://plus.google.com/104600644661703025213" target="_blank">+Brad Currie</a>  @<a href="https://twitter.com/bcurrie5">bcurrie5 </a>who run fantastic chats and link people together. (Steven Anderson  <a href="http://www.twitter.com/web20classroom">@web20classroom</a> too and so many others! If they run a chat, I'm going to follow them - that is how important the bridge builders are.) They are important because they link all kinds of people and work hard at promoting important conversations.<br /></li><li><b>Exceptional people with exceptional ideas</b><br />I do follow some people who do not follow me back. I create a whitelist in my <a href="http://www.socialbro.com/">Social Bro</a> app and I will follow them. <a href="http://www.michaelhyatt.com/">Michael Hyatt</a> <a href="https://twitter.com/michaelhyatt">@michaelhyatt</a>, author of <a href="http://www.amazon.com/gp/product/159555503X/ref=as_li_ss_tl?ie=UTF8&camp=1789&creative=390957&creativeASIN=159555503X&linkCode=as2&tag=httpwwwbrighc-20" id="static_txt_preview" style="background-color: white; color: #996633; font-family: Verdana, Arial, Helvetica, sans-serif; font-size: small; text-align: center;" target="_blank">Platform: Get Noticed in a Noisy World</a>  is one of those people. I listen to <a href="http://michaelhyatt.com/thisisyourlife">his podcas</a>t each morning and am going back and listening to old ones. His existence in the world makes my existence in the world better. They don't have to follow me back.<br /></li><li><b>Friends</b><br />There are so many cool people in the world with interesting stories. Oh, to have a pad of paper and a line of people so as to hear all of them! If I sit down and talk to you for a bit at a conference and if you tweet me that we had a great conversation - you've just cemented that relationship. I follow you and we can now continue conversing. Sometimes when I'm talking with a person, I'll get their handle right then and tweet them so we can do that.<br /></li><li><b>Educators, especially teachers, principals, superintendents, librarians, curriculum directors, and IT or parents who advocate for good education wherever their child is in school. I also love to follow homeschooling parents b/c they are teachers too!</b><br /><br />But, that said, if you don't put this stuff in your bio and you put something random about how you like to skydive and eat coffee beans whole, I'm not going to know that about you. I often use my follower management tool, Social Bro, to search for those who have the word "teacher" in their profile. I hunger to look at my beautiful tweet stream and see the random beauty of educators from around the world talking. I have no desire to make myself look important by only following 145 people - I have private lists to drill down to that level.</li></ul></div><div><br /></div><h2>I unfollow people who:</h2><div><ul><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgGIfiren1GUoeDxdFyn9oRQ-O20vS5RboX3uddbbfJtawi7gOGjPNfJN0loSQMtZu_V9tuPhCHh4eoIkWelPDZeI5aoB45fC0b7_fGN0f8V0aq-HP3WogC3GAGWn2XIMuvH5xxAWjR_HEi/s1600/1-kimberly-twitter-follow.JPG" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><br /></a><li><b>Haven't tweeted in 30 days.</b> <br />It doesn't matter if you're popular. If you haven't tweeted in 30 days then you're not engaged on Twitter and likely may end up taken over by a spammer.<br /></li><li><b>Have no rhyme or reason to what they tweet.</b><br />Thousands of retweets? A bunch of junk? If I see that you're just indiscriminately tweeting junk, I kind of feel like you're the old aunt who auto forwards everything in their inbox without reading. Her mail goes in my spam and your Twitter account will be unfollowed.<br /></li><li><b>Are consistently mean, demeaning, and use Twitter to belittle others.</b><br />There are those who make a career out of insulting people. I have no time for them in my life - I work with teenagers, that is hard enough.<br /></li><li><b>Spam me with dm without admitting it.</b><br />If you get a virus and dm me - contact me and let me know it was a virus, or I'll unfollow you. If you indiscriminately dm me asking me to do things for you all the time - you don't care, you just want * want * want - I'm unfollowing. If I want someone in my life who just wants to take from me all the time - I'll go home and talk to my teenagers. (I do love teenagers, but if you've had them, your empty pockets and full calendar understand.)<br /></li><li><b>Consistently steal my tweets verbatim without credit.</b><br />Yes, there are unimaginative people who just copy the tweets of others - verbatim, even in the same order. When I saw it happening, I started using the <a href="http://sharedby.co/">sharedby</a> tool which pops a frame at the top of the tweet giving me credit anyway. It isn't that it is such a huge deal but when it is companies and people making money off Twitter who just want to take all those hours I spend researching and just copy it without credit, that is bad netiquette.<br /></li><li><b>Don't converse.</b><br />I use a great tool that social media genius <a href="http://jureklepic.com/">Jure Klepic</a> @<a href="https://twitter.com/jkcallas">jkcallas</a> (a friend of <a class="zem_slink" href="http://www.angelamaiers.com/" rel="homepage" target="_blank" title="Angela Maiers">Angela Maiers</a>) recommended when I talked to him at Microsoft. <a href="http://socialbro.com/">Social bro </a>helps me manage Twitter followers. I go in once a week and see who is following me that I'm not following back (I can't do this daily - it is too many people) and look at them. I look at those I'm following who just never talk back to me. I'll look at what they've been tweeting lately: is it about education? Do those tweets make me a better person? If they don't converse with me and don't meet this criteria, I'll unfollow.<br /></li><li><b>Who try to game the system.</b><br />These are Twitter scum in my book. I don't care how interesting you are. If you follow as many as you can and unfollow just after they follow you back hoping that not everyone will unfollow you - you're gaming the system and that wasn't what Twitter is supposed to be. I will unfollow you AND blacklist you in socialbro (which means I'll never see your name again.)<br /></li><li><b>People who are users.</b><br />I'm <i>just </i>a teacher who has been blessed with many great friends online. There are "important" thought leaders who won't follow me, won't converse with me, and completely ignore me when I reach out to ask a question. They have NO teachers in their list of people they follow except those who look like cookie cutter copies of themselves. However, these people will often email me asking me to promote their book or retweet something or do this or that for them. They want to use my followers but don't care a rip about me at all when I need help or have a question.<br /><br />I love people who love average everyday teachers and if they are going ignore me because I'm just a teacher then how will they feel about other teachers? Call it "I'm taking my tweets and flying to the roost" but truthfully I know I'm nothing and these people won't miss me or even care. I can add them to a list and read their stuff to stay abreast but many of them don't even use popular educational hashtags to make it easier to see what they are talking about. I'd rather talk with real educators who I love because the greatest teachers have a lot of love... and humility. Those are the kinds of people I'd like to be around. I like cooperative collaborators in my stream.<br /><br />Others just want to use me for a retweet and beg incessantly for me to promote their product, book, or whatever but have never engaged in conversation, never talked in the community. They are users and will be lucky to even get a follow.<br /></li></ul><h2>I won't follow you if:</h2></div><div><ul><li><b>Your profile says nothing about you.</b><br />I have no idea if you're legit or not.<br /></li><li><b>Your avatar is still a new egg.</b><br />You haven't taken the time to put yourself out there. I want to make sure people are real.<br /></li><li><b>You don't follow anyone at all.</b></li><li><b>Your twitter stream shows you're here to be followed not to converse.</b><br />Desperate divas get no dates. If you want to be followed, be helpful, be giving, think of others first. <span style="color: red;"><b>Being followed is a by product of being kind and helpful</b></span> -- or being a celebrity. Celebrities won't read this post anyway. Life is full of enough people full of themselves - I fund such an attitude repugnant.<br /></li><li><b>You're a celebrity.</b><br />Exception: Jimmy Fallon. @<a href="https://twitter.com/jimmyfallon">jimmyfallon</a> The dude is hilarious. His Twitter games are fun to play.</li></ul><div>I'd love to hear your guidelines. If you're on Twitter, these rules will change over time. Twitter is important to me because it links me quickly and easily with some of the finest people on the planet. I'm always looking for great educators and teachers to follow or anyone who loves teaching kids. </div></div><div class="zemanta-pixie" style="height: 15px; margin-top: 10px;"><a class="zemanta-pixie-a" href="http://www.zemanta.com/?px" title="Enhanced by Zemanta"><img alt="Enhanced by Zemanta" class="zemanta-pixie-img" src="http://img.zemanta.com/zemified_c.png?x-id=41fba8d5-2c28-442f-bc69-3797687bdde9" style="border: none; float: right;" /></a></div></div>

An Easy Guide to Gaining Followers and Being Followed on Twitter

Twitter (Photo credits: www.mysecuritysign.com ) Twitter is an interesting mix of people. As you join Twitter, you need to decide how you ...

Read more »

Cancer Physicians Attack High Drug Costs - NYTimes.com

<base href="data:"><div style="font-size: 14px; color: black; text-align: left; "><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">With the cost of some lifesaving <a href="http://health.nytimes.com/health/guides/disease/cancer/overview.html?inline=nyt-classifier" title="In-depth reference and news articles about Cancer." class="meta-classifier" style="color: rgb(102, 102, 153); text-decoration: none; ">cancer</a> drugs exceeding $100,000 a year, more than 100 influential cancer specialists from around the world have taken the unusual step of banding together in hopes of persuading some leading pharmaceutical companies to bring prices down.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">Prices for cancer drugs have been part of the debate over health care costs for several years — and recently led to a public protest from doctors at a major cancer center in New York. But the decision by so many specialists, from more than 15 countries on five continents, to join the effort is a sign that doctors, who are on the front lines of caring for patients, are now taking a more active role in resisting high prices. In this case, some of the specialists even include researchers with close ties to the pharmaceutical industry.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">The doctors and researchers, who specialize in the potentially deadly blood cancer known as chronic myeloid leukemia, contend in a commentary published online by a medical journal Thursday that the prices of drugs used to treat that disease are astronomical, unsustainable and perhaps even immoral.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">They suggested that charging high prices for a medicine needed to keep someone alive is profiteering, akin to jacking up the prices of essential goods after a natural disaster.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">"Advocating for lower drug prices is a necessity to save the lives of patients" who cannot afford the medicines, <a title="The commentary in the journal Blood [PDF]. " href="http://bloodjournal.hematologylibrary.org/content/early/2013/04/23/blood-2013-03-490003.full.pdf+html" style="color: rgb(102, 102, 153); text-decoration: none; ">they wrote in Blood,</a> the journal of the American Society of Hematology.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">While noting that the cost of drugs for many other cancers were just as high, the doctors focused on what they know best — the medicines for chronic myeloid leukemia, like Gleevec, which is enormously profitable for Novartis. Among the critics is<a title="Dr. Druker's bio page. " href="http://www.ohsu.edu/xd/health/services/cancer/about-us/druker/profile.cfm" style="color: rgb(102, 102, 153); text-decoration: none; "> Dr. Brian Druker, </a>who was the main academic developer of Gleevec and had to prod Novartis to bring it to market.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">Novartis argues that few patients actually pay the full cost of the drug and that prices reflect the high cost of research and the value of a drug to patients.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">Gleevec entered the market in 2001 at a price of about $30,000 a year in the United States, the doctors wrote. Since then, the price has tripled, it said, even as Gleevec has faced competition from five newer drugs. And those drugs are even more expensive.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">The prices have been the subject of intense debate elsewhere as well. The Supreme Court in India ruled recently that the drug could not be patented, clearing the way for use of far less expensive generic alternatives.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">Some of the doctors who signed on to the commentary said they were inspired by physicians at the Memorial Sloan-Kettering Cancer Center in New York, who last fall refused to use a new <a href="http://health.nytimes.com/health/guides/disease/colon-cancer/overview.html?inline=nyt-classifier" title="In-depth reference and news articles about Colon Cancer." class="meta-classifier" style="color: rgb(102, 102, 153); text-decoration: none; ">colon cancer</a> drug, Zaltrap, because it was twice as expensive as another drug without being better.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">After those doctors publicized their objections <a title="The article." href="http://www.nytimes.com/2012/10/15/opinion/a-hospital-says-no-to-an-11000-a-month-cancer-drug.html" style="color: rgb(102, 102, 153); text-decoration: none; ">in an Op-Ed article</a> in The New York Times, Sanofi, which markets Zaltrap, effectively <a title="Related article. " href="http://www.nytimes.com/2012/11/09/business/sanofi-halves-price-of-drug-after-sloan-kettering-balks-at-paying-it.html" style="color: rgb(102, 102, 153); text-decoration: none; ">cut the price in half</a>.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">What impact the new commentary will have remains to be seen. The authors, however, call merely for a dialogue on pricing to begin.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">The leader of the protest is <a title="Dr. Kantarjian's bio page. " href="http://faculty.mdanderson.org/Hagop_Kantarjian/Default.asp" style="color: rgb(102, 102, 153); text-decoration: none; ">Dr. Hagop M. Kantarjian</a>, chairman of the leukemia department at the prestigious MD Anderson Cancer Center in Houston.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">Many of the roughly 120 doctors who were co-authors of the commentary — about 30 of whom are from the United States — work closely with pharmaceutical companies on research and clinical trials. They say they favor a healthy pharmaceutical industry, but think prices are much higher than they need to be to ensure that.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">"If you are making $3 billion a year on Gleevec, could you get by with $2 billion?" Dr. Druker, who is now director of the Knight Cancer Institute at Oregon Health and Science University, said in an interview. "When do you cross the line from essential profits to profiteering?"</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">Gleevec's sales were $4.7 billion in 2012, making it Novartis's best-selling drug. A newer Novartis leukemia drug, Tasigna, had sales of $1 billion.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">Novartis said in a statement released Thursday: "We recognize that sustainability of health care systems is a complex topic and we welcome the opportunity to be part of the dialogue."</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">It said that its investment in Gleevec continued after the initial approval, expanding the drug's use to other diseases. It also said that it provided Gleevec or Tasigna free to 5,000 uninsured or underinsured Americans each year and to date had provided free drugs to more than 50,000 people in low-income countries.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">Novartis and the manufacturers of the other drugs for chronic myeloid leukemia say the prices reflect the value of the drug. While many cancer drugs with equally high prices extend life by only a few months on average, it is widely agreed that Gleevec and rivals are near-miracle medicines that essentially turn a death sentence into a chronic disease like <a href="http://health.nytimes.com/health/guides/disease/diabetes/overview.html?inline=nyt-classifier" title="In-depth reference and news articles about Diabetes." class="meta-classifier" style="color: rgb(102, 102, 153); text-decoration: none; ">diabetes</a>.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">"It is a little surprising that their focus is in a cancer where the small-molecule medicines have had the greatest impact on long-term benefit," said Dr. Harvey J. Berger, chief executive of Ariad Pharmaceuticals, which sells the newest and most expensive of the leukemia drugs, Iclusig.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">Dr. Berger said the price of Iclusig was $115,000 a year, not the $138,000 a year cited in the commentary. Pfizer said the price of its drug, Bosulif, also was overstated in the piece. The manufacturers cite the price at which they sell to wholesalers, while the authors of the commentary were referring to a price they say better reflects what is charged by a pharmacy to patients.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">The other drugs for chronic myeloid leukemia are Sprycel from Bristol-Myers Squibb and Synribo from Teva.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">The commentary noted that despite drug company programs, a minority of the estimated 1.2 million to 1.5 million people in the world with chronic myeloid leukemia were receiving one of the drugs. In many developing nations, it said, cancer experts were advocating risky bone marrow transplants because that is a one-time procedure that is cheaper than continuous treatment with one of the drugs.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">The article also said the survival rate for patients in the United States appeared to be less than it should be, perhaps because costs are forcing patients to not take their medicine. Prices for the drugs are twice as high in the United States as in many other countries, which often apply some government pressure or price controls to keep drug costs down.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">Even if out-of-pocket costs can be low, health systems in general still must pay for the drugs, the commentary says. And some patients say assistance programs are not always easy to use.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">Raven Riedesel of Winlock, Wash., said she had been turned down by various charities — though she hadn't yet tried Novartis itself — because her husband, a pipe fitter, makes too much money. Yet the insurance from his union would require her to pay $1,200 to $1,600 a month as a co-payment for Tasigna.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">"It would take everything that we had left over after buying necessities and paying our bills," said Ms. Riedesel, 28, a mother of two young children. She is now in a clinical trial allowing her to obtain Tasigna free; the trial will end in November.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">Patients in the United States circulated <a title="A Web site about the petition. " href="http://www.change.org/petitions/novartis-and-us-representatives-in-congress-reduce-to-patients-the-cost-of-the-drug-gleevec" style="color: rgb(102, 102, 153); text-decoration: none; ">an online petition</a> last year protesting the price of Gleevec, but the effort was dropped after receiving about 400 signatures.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">Cheap generic versions could enter the American market as early as 2015 when the main patent on Gleevec expires. Novartis might try to assert other patents to stave off competition, however. It is also trying to shift patients to Tasigna, which has a longer patent life.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">Dr. John M. Goldman, emeritus professor of hematology at Imperial College in London and a co-author of the commentary, said he knew several researchers who declined to become authors because they feared losing research money from the industry.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">Dr. Kantarjian, the lead author, said that was a risk.</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); "><font class="Apple-style-span" face="'Helvetica Neue'">"I am sure I am going to be blackballed," he said. "My research career will be hurt."</font></p><p itemprop="articleBody" style="color: black; font-size: 1.2em; margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; line-height: 24px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-align: -webkit-auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); position: static; z-index: auto; "><font class="Apple-style-span" face="'Helvetica Neue'">But he said it was time to speak out. "Pharmaceutical companies have lost their moral sense," he said. Prices, he added, "are getting to the point where it is becoming unsustainable."</font></p></div><a href="http://www.nytimes.com/2013/04/26/business/cancer-physicians-attack-high-drug-costs.html?src=me&ref=general&pagewanted=print"><font class="Apple-style-span" face="'Helvetica Neue'">http://www.nytimes.com/2013/04/26/business/cancer-physicians-attack-high-drug-costs.html?src=me&ref=general&pagewanted=print</font></a><div style="font-family: Helvetica; font-size: 14px; color: black; text-align: left; "><br class="webkit-block-placeholder"></div>

Cancer Physicians Attack High Drug Costs - NYTimes.com

With the cost of some lifesaving  cancer  drugs exceeding $100,000 a year, more than 100 influential cancer specialists from around the worl...

Read more »